-1.09%
16.83%
8.26%
-27.87%
-29.04%
-47.30%
-13.49%
AI Spotlight on TECN
Company Description
Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories.It operates through Life Sciences Business and Partnering Business segments.The company offers liquid handling and automation, microplate readers and washers, consumables, NGS reagents, immunoassays and microbodies, and software; Tecan Laberwax, an automation solution; Resolvex, a smart sample preparation solution for use in genomics, synthetic biology, drug discovery, analytical chemistry, cell biology, protein science, applied markets, and ELISA solutions.
It also develops and manufactures laboratory instrument manufacturers with essential components comprising precision pumps, valves, robotic arms, and developer software for life science research, diagnostics, and various other industries; Synergence, platform-based automation solution; and Freedom EVO and Fluent instruments.The company operates in Switzerland and Other European countries, North America, Asia, and internationally.Tecan Group AG was founded in 1980 and is headquartered in Männedorf, Switzerland.
Market Data
| Last Price | 236 |
| Change Percentage | -1.09% |
| Open | 239.2 |
| Previous Close | 238.6 |
| Market Cap ( Millions) | 3019 |
| Volume | 34499 |
| Year High | 392 |
| Year Low | 192.7 |
| M A 50 | 213.3 |
| M A 200 | 273.13 |
Financial Ratios
| FCF Yield | 3.43% |
| Dividend Yield | 1.42% |
| ROE | 7.36% |
| Debt / Equity | 22.44% |
| Net Debt / EBIDTA | 127.48% |
| Price To Book | 2.15 |
| Price Earnings Ratio | 29.78 |
| Price To FCF | 29.13 |
| Price To sales | 3.02 |
| EV / EBITDA | 19.84 |
News
- Jan -27 - Tecan Introduces Veya: Bringing Digital, Scalable Automation to Labs Worldwide
- Jan -08 - Tecan meets revised sales outlook for fiscal year 2024
- Jan -06 - Tecan to present at upcoming Investor Conferences
- Oct -22 - Tecan’s Capital Markets Day highlights strategic growth drivers, groundbreaking innovation and product launches
- Oct -16 - Tecan provides update on current trading and revised outlook for full year 2024
- Aug -13 - Tecan crashes 15% after slashing sales forecast
- Aug -13 - Tecan reports financial results for the first half of 2024 and revises its outlook for full year 2024
- Aug -06 - Tecan schedules conference call on August 13th to discuss half year 2024 financial results
- Jun -24 - Tecan appoints Mukta Acharya Head of the Life Sciences Business division
- Apr -18 - Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by the Board of Directors
- Apr -05 - Is Tecan Group AG's (VTX:TECN) Latest Stock Performance A Reflection Of Its Financial Health?
- Mar -26 - Annual General Meeting 2024: Tecan proposes election of an additional member of the Board of Directors and various amendments to the Articles of Incorporation
- Mar -15 - Tecan Group Full Year 2023 Earnings: EPS Beats Expectations
- Mar -14 - Tecan Group AG Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
- Mar -12 - Tecan reports solid underlying sales growth and an increase in profitability and net profit for full year 2023
- Mar -05 - Tecan schedules conference call on March 12 to discuss Full-Year 2023 Financial Results
- Feb -26 - With 70% ownership, Tecan Group AG (VTX:TECN) boasts of strong institutional backing
- Jan -19 - Tecan Group AG's (VTX:TECN) Intrinsic Value Is Potentially 18% Below Its Share Price
- Jan -08 - Tecan reports underlying sales growth of 6.3% for full year 2023
- Jan -08 - Tecan to present at upcoming Investor Conferences
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Partnering
Expected Growth : 5 %
What the company do ?
Partnering with Tecan Group AG enables collaboration on laboratory automation and liquid handling solutions, driving innovation and advancing life science research.
Why we expect these perspectives ?
Tecan Group AG's partnering strategy drives growth through expanded market access, increased R&D capabilities, and improved operational efficiency. This partnership enables Tecan to leverage its partner's expertise, accelerating innovation and time-to-market for new products. Additionally, it enhances Tecan's competitive position, allowing the company to capitalize on emerging trends in life sciences and diagnostics.
Segment n°2 -> Life Sciences
Expected Growth : 7 %
What the company do ?
Life Sciences from Tecan Group AG refers to the development of innovative solutions for life science research, diagnostics, and biotechnology applications.
Why we expect these perspectives ?
Tecan Group AG's Life Sciences segment growth is driven by increasing demand for automated laboratory workflows, rising adoption of genomics and precision medicine, and growing investments in biotech and pharma R&D. Additionally, the segment benefits from the company's strong brand reputation, innovative product offerings, and strategic partnerships.
Tecan Group Ag Products
| Product Range | What is it ? |
|---|---|
| Liquid Handling Systems | Automated liquid handling systems for laboratory applications, including pipetting, dispensing, and sampling. |
| Detection Instruments | Microplate readers and washers for biochemical and cell-based assays, including absorbance, fluorescence, and luminescence detection. |
| Automation Platforms | Customizable automation platforms for laboratory workflows, including sample preparation, liquid handling, and detection. |
| Software and Informatics | Data management and analysis software for laboratory workflows, including data integration, visualization, and reporting. |
| OEM and Partnering Solutions | Customized OEM solutions for instrument manufacturers and partnering opportunities for life science companies. |
| Services and Support | Comprehensive service and support offerings, including maintenance, repair, and training for Tecan's products. |
Tecan Group AG's Porter Forces
Threat Of Substitutes
The threat of substitutes for Tecan Group AG is moderate, as there are alternative products and services available in the market, but they are not significantly cheaper or better than Tecan's offerings.
Bargaining Power Of Customers
The bargaining power of customers is low, as Tecan Group AG has a diverse customer base and no single customer accounts for a significant portion of its revenue.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate, as Tecan Group AG relies on a few key suppliers for critical components, but it also has some bargaining power due to its large scale of operations.
Threat Of New Entrants
The threat of new entrants is low, as entering the life sciences industry requires significant investments in research and development, manufacturing, and regulatory compliance.
Intensity Of Rivalry
The intensity of rivalry is high, as Tecan Group AG operates in a highly competitive industry with several established players, and the company needs to continuously innovate and improve its products and services to maintain its market share.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 18.98% |
| Debt Cost | 3.95% |
| Equity Weight | 81.02% |
| Equity Cost | 7.04% |
| WACC | 6.45% |
| Leverage | 23.43% |
Tecan Group AG : Quality Control
Tecan Group AG passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| YPSN.SW | Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and … |
| AMP.MI | Amplifon S.p.A. retails hearing care products and services that help people rediscover various emotions of sound. The company offers ampli-easy, ampli-mini, ampli-connect, and ampli-energy hearing devices. It also provides fitting … |
| EKTA-B.ST | Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac … |
| AFX.DE | Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. … |
| GXI.DE | Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Elekta
A-Score
1-Year Total Return ->
🥈
Ypsomed
A-Score
1-Year Total Return ->
🥉
Amplifon
A-Score
1-Year Total Return ->
4
Tecan
A-Score
1-Year Total Return ->
5
Gerresheimer
A-Score
1-Year Total Return ->
6
